AIMS/HYPOTHESIS: The serine/threonine kinase Akt/protein kinase B (PKB) is required for the metabolic actions of insulin. Controversial data have been reported regarding Akt defective activation in the muscle of type 2 diabetic patients. Because three Akt isoforms exist, each having a distinct physiological role, we investigated the contribution of isoform-specific defects to insulin signalling in human muscle. METHODS: The phosphorylation pattern and kinase activity of each Akt isoform were compared in primary myotubes from healthy control participants and type 2 diabetic patients. Phosphorylation of Ser(473) and of Thr(308) in each isoform was determined after immunoprecipitation in myotubes treated or not with insulin. RESULTS: Muscle cells from diabetic patients displayed defective insulin action and a drastic reduction of insulin-stimulated activity of all Akt isoforms. This was associated with specific defects of their phosphorylation pattern in response to insulin, with impaired Akt2- (and to a lower extent Akt3-) Ser(473) phosphorylation, and with altered Akt1-Thr(308) phosphorylation. These defects were not due to faulty phosphoinositide-dependent protein kinase 1 (PDK1) production or activation. Rather, we found higher levels of the Akt2-Ser(473)-specific protein phosphatase PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) in muscle from diabetic patients, which may contribute to the alteration of Akt2-Ser(473) phosphorylation. CONCLUSIONS/ INTERPRETATION: These results suggest that several mechanisms affecting Akt isoforms, including deregulated production of PHLPP1, could underlie the alterations of skeletal muscle insulin signalling in type 2 diabetes. Taking into account the recently described isoform-specific metabolic functions of Akt, our results provide mechanistic insight that may contribute to the defective regulation of glucose and lipid metabolisms in the muscle of diabetic patients.
AIMS/HYPOTHESIS: The serine/threonine kinase Akt/protein kinase B (PKB) is required for the metabolic actions of insulin. Controversial data have been reported regarding Akt defective activation in the muscle of type 2 diabeticpatients. Because three Akt isoforms exist, each having a distinct physiological role, we investigated the contribution of isoform-specific defects to insulin signalling in human muscle. METHODS: The phosphorylation pattern and kinase activity of each Akt isoform were compared in primary myotubes from healthy control participants and type 2 diabeticpatients. Phosphorylation of Ser(473) and of Thr(308) in each isoform was determined after immunoprecipitation in myotubes treated or not with insulin. RESULTS: Muscle cells from diabeticpatients displayed defective insulin action and a drastic reduction of insulin-stimulated activity of all Akt isoforms. This was associated with specific defects of their phosphorylation pattern in response to insulin, with impaired Akt2- (and to a lower extent Akt3-) Ser(473) phosphorylation, and with altered Akt1-Thr(308) phosphorylation. These defects were not due to faulty phosphoinositide-dependent protein kinase 1 (PDK1) production or activation. Rather, we found higher levels of the Akt2-Ser(473)-specific protein phosphatase PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) in muscle from diabeticpatients, which may contribute to the alteration of Akt2-Ser(473) phosphorylation. CONCLUSIONS/ INTERPRETATION: These results suggest that several mechanisms affecting Akt isoforms, including deregulated production of PHLPP1, could underlie the alterations of skeletal muscle insulin signalling in type 2 diabetes. Taking into account the recently described isoform-specific metabolic functions of Akt, our results provide mechanistic insight that may contribute to the defective regulation of glucose and lipid metabolisms in the muscle of diabeticpatients.
Authors: Rachael M Easton; Han Cho; Kristin Roovers; Diana W Shineman; Moshe Mizrahi; Mark S Forman; Virginia M-Y Lee; Matthias Szabolcs; Ron de Jong; Tilman Oltersdorf; Thomas Ludwig; Argiris Efstratiadis; Morris J Birnbaum Journal: Mol Cell Biol Date: 2005-03 Impact factor: 4.272
Authors: Karim Bouzakri; Anna Zachrisson; Lubna Al-Khalili; Bei B Zhang; Heikki A Koistinen; Anna Krook; Juleen R Zierath Journal: Cell Metab Date: 2006-07 Impact factor: 27.287
Authors: Oliver Tschopp; Zhong-Zhou Yang; Daniela Brodbeck; Bettina A Dummler; Maja Hemmings-Mieszczak; Takashi Watanabe; Thomas Michaelis; Jens Frahm; Brian A Hemmings Journal: Development Date: 2005-06-01 Impact factor: 6.868
Authors: H Cho; J Mu; J K Kim; J L Thorvaldsen; Q Chu; E B Crenshaw; K H Kaestner; M S Bartolomei; G I Shulman; M J Birnbaum Journal: Science Date: 2001-06-01 Impact factor: 47.728
Authors: A Krook; M Björnholm; D Galuska; X J Jiang; R Fahlman; M G Myers; H Wallberg-Henriksson; J R Zierath Journal: Diabetes Date: 2000-02 Impact factor: 9.461
Authors: Naveen Sharma; Edward B Arias; Mini P Sajan; James G MacKrell; Abhijit D Bhat; Robert V Farese; Gregory D Cartee Journal: J Appl Physiol (1985) Date: 2010-03-25
Authors: K T Tonks; Y Ng; S Miller; A C F Coster; D Samocha-Bonet; T J Iseli; A Xu; E Patrick; J Y H Yang; J R Junutula; Z Modrusan; G Kolumam; J Stöckli; D J Chisholm; D E James; J R Greenfield Journal: Diabetologia Date: 2013-01-24 Impact factor: 10.122
Authors: Piran Shelley; Malgorzata S Martin-Gronert; Anthea Rowlerson; Lucilla Poston; S J R Heales; Iain P Hargreaves; Josie M McConnell; Susan E Ozanne; Denise S Fernandez-Twinn Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-06-17 Impact factor: 3.619